News stories about Sagent Pharmaceuticals (NASDAQ:SGNT) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sagent Pharmaceuticals earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.3612187339698 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://ledgergazette.com/2017/10/09/sagent-pharmaceuticals-sgnt-earns-media-sentiment-score-of-0-23.html.
Sagent Pharmaceuticals Company Profile
Sagent Pharmaceuticals, Inc is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market.
Receive News & Ratings for Sagent Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.